Martin Kudr

Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Craig M. McDonald, Craig Campbell, Ricardo Erazo Torricelli et al. · The Lancet · 2017 · 446 citations · Full text

Rare Diseases, Urology, Clinical Trials +5

Seizure outcome and use of antiepileptic drugs after epilepsy surgery according to histopathological diagnosis: a retrospective multicentre cohort study

Herm J. Lamberink, Willem M. Otte, Ingmar Blümcke et al. · The Lancet Neurology · 2020 · 334 citations · Full text

Seizure Outcome, Antiepileptic Drugs, Epilepsy Surgery +5

A randomized placebo-controlled phase 3 trial of an antisense oligonucleotide, drisapersen, in Duchenne muscular dystrophy

Nathalie Goemans, Eugenio Mercuri, Hirofumi Komaki et al. · Neuromuscular Disorders · 2017 · 119 citations · Full text

Duchenne Muscular Dystrophy, Medicine, Clinical Trials +5

Predictors of seizure‐free outcome after epilepsy surgery for pediatric tuberous sclerosis complex

Pavel Kršek, Alena Jahodová, Martin Kynčl et al. · Epilepsia · 2013 · 61 citations · Full text

SISCOM and FDG‐PET in patients with non‐lesional extratemporal epilepsy: correlation with intracranial EEG, histology, and seizure outcome

Martin Kudr, Pavel Kršek, Petr Marusič et al. · Epileptic Disorders · 2013 · 47 citations